Bausch Health controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile3 entries
2020
SEC revenue-recognition settlement
The SEC announced that Bausch Health agreed to pay a penalty to settle charges involving improper revenue recognition and misleading disclosures. Former executives also agreed to monetary settlements. The company did not admit wrongdoing in the settlement.
2015
Philidor distribution and accounting controversy
Allegations concerning Valeant’s relationship with Philidor Rx Services raised questions about revenue recognition, pharmacy operations, billing practices and the routing of customers toward Valeant products. Valeant rejected the allegations but ended the relationship and faced multiple investigations.
2015
Drug-pricing controversy
Valeant attracted political and regulatory criticism for substantial price increases affecting several acquired or licensed medicines, including Nitropress, Isuprel, Glumetza and flucytosine.